Merrimack Pharmaceuticals, Inc. (MACK): Price and Financial Metrics


Merrimack Pharmaceuticals, Inc. (MACK): $11.45

0.04 (+0.35%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add MACK to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

MACK Stock Price Chart Interactive Chart >

Price chart for MACK

MACK Price/Volume Stats

Current price $11.45 52-week high $13.66
Prev. close $11.41 52-week low $3.00
Day low $11.32 Volume 115,300
Day high $11.62 Avg. volume 256,611
50-day MA $11.64 Dividend yield N/A
200-day MA $6.66 Market Cap 153.54M

Merrimack Pharmaceuticals, Inc. (MACK) Company Bio


Merrimack Pharmaceuticals is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of cancer. The company was founded in 1993 and is based in Cambridge, Massachusetts.


MACK Latest News Stream


Event/Time News Detail
Loading, please wait...

MACK Latest Social Stream


Loading social stream, please wait...

View Full MACK Social Stream

Latest MACK News From Around the Web

Below are the latest news stories about MERRIMACK PHARMACEUTICALS INC that investors may wish to consider to help them evaluate MACK as an investment opportunity.

Merrimack Pharmaceuticals (NASDAQ:MACK) Is In A Strong Position To Grow Its Business

We can readily understand why investors are attracted to unprofitable companies. For example, Merrimack Pharmaceuticals...

Yahoo | January 23, 2023

12 Best Performing Biotech Stocks in 2022

In this article, we discuss 12 best performing biotech stocks in 2022. If you want to see more stocks in this selection, check out 5 Best Performing Biotech Stocks in 2022. Fitch Ratings has assigned a Neutral rating to the global pharmaceutical and biotech industry, which indicates the assumption of a collaborative operating backdrop in […]

Yahoo | December 29, 2022

Bullish Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) insiders filled their treasuries with US$574k worth of stock over last year

Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like...

Yahoo | December 13, 2022

Merrimack Pharmaceuticals Extends Section 382 Net Operating Loss Rights Plan

CAMBRIDGE, Mass., December 05, 2022--MERRIMACK PHARMACEUTICALS EXTENDS SECTION 382 NET OPERATING LOSS RIGHTS PLAN

Yahoo | December 5, 2022

The Zacks Analyst Blog Highlights Merrimack Pharmaceuticals, Moderna and Seagen

Highlights Merrimack Pharmaceuticals, Moderna and Seagen are included in this Analyst Blog.

Yahoo | November 17, 2022

Read More 'MACK' Stories Here

MACK Price Returns

1-mo 9.46%
3-mo 200.52%
6-mo 124.95%
1-year 143.62%
3-year 246.97%
5-year 3.71%
YTD -0.09%
2022 193.09%
2021 -43.25%
2020 118.73%
2019 -18.39%
2018 -62.34%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6356 seconds.